Trajectories of neutrophil-to-lymphocyte ratios during neoadjuvant chemotherapy correlate with short- and long-term outcomes in gastric cancer: a group-based trajectory analysis

Table 4 Trajectory group hazard ratio (HR) for overall survival

	Unadjusted model		Preliminary adjusted model^a		Fully adjusted model^b
OS	Hazard Ratio (95% CI)	p value	Hazard Ratio (95% CI)	p value	Hazard Ratio (95% CI)	p value
Stable	Reference		Reference		Reference
Ascent-descend	1.621(1.052–2.497)	0.029	1.639(1.061–2.530)	0.026	1.830(1.127–2.969)	0.014
Continuous descent	2.088(1.306–3.339)	0.002	2.025(1.250–3.281)	0.004	1.913(1.092–3.351)	0.023

Note ^a Adjusted for age, gender, BMI, ECOG scoring scale
^b Additional adjusted for CT TNM stage, Clinical response per RECIST criteria, Tumor location, Resection range, Multiorgan resection (yes/no), Intraoperative blood loss, number of lymph node dissections, Lymphovascular invasion (yes/no), Neural infiltration(yes/no), Tumor regression grade, ypTNM stage

ISSN: 1471-2407